# Exploring the Potential of Donkey Milk in Enhancing Pneumonia Treatment Outcomes—Pilot Study

**Authors:** Violeta Kolarov, Anika Trudić, Maja Bogdan, Jovan Javorac, Ivana Čabarkapa, Dragana Tomanić, Ljubiša Šarić

PMC · DOI: 10.3390/antibiotics15020121 · Antibiotics · 2026-01-26

## TL;DR

This pilot study explores whether donkey milk can improve pneumonia treatment outcomes when used alongside antibiotics.

## Contribution

The study is the first to investigate donkey milk as an adjunct therapy for community-acquired pneumonia in a clinical setting.

## Key findings

- Donkey milk supplementation led to faster reductions in CRP and PCT levels in pneumonia patients.
- Patients receiving donkey milk had greater radiological improvement and shorter hospital stays.
- No adverse effects were observed, and compliance with donkey milk supplementation was high.

## Abstract

Background/Objectives: Community-acquired pneumonia (CAP) is a major cause of hospitalization and mortality worldwide, with growing interest in adjunctive therapies to enhance treatment outcomes. Donkey milk, long used in traditional medicine for respiratory illnesses, contains bioactive compounds with antimicrobial, anti-inflammatory, and immunomodulatory properties that may benefit patients with CAP. Methods: Sixty hospitalized patients were prospectively allocated into two groups based on their consent to receive adjunctive donkey milk supplementation: one received standard antibiotic therapy plus 250 mL of pasteurized donkey milk twice daily for one month, while the control group received antibiotics alone. Results: Patients consuming donkey milk showed significantly faster reductions in C-reactive protein CRP and procalcitonin PCT levels, greater radiological improvement (p < 0.001), and a shorter average hospital stay (12.46 vs. 14.16 days). Logistic regression analysis identified donkey milk consumption as a significant predictor of shorter hospital stay. Importantly, no adverse effects were reported, and compliance with the supplementation was high. Conclusions: These findings suggest that pasteurized donkey milk may serve as a safe and effective natural adjunct to standard antibiotic therapy in managing CAP, with potential to enhance recovery and reduce hospital stay. Further large-scale studies are needed to validate these results and explore broader applications of donkey milk in infectious diseases.

## Linked entities

- **Diseases:** pneumonia (MONDO:0005249)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, LALBA (lactalbumin alpha) [NCBI Gene 3906] {aka HAMLET, LYZG}, LYZ (lysozyme) [NCBI Gene 4069] {aka AMYLD5, LYZF1, LZM}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, CALCA (calcitonin related polypeptide alpha) [NCBI Gene 796] {aka CALC1, CGRP, CGRP-I, CGRP-alpha, CGRP1, CT}
- **Diseases:** cramps (MESH:D009120), impaired swallowing (MESH:D003680), death (MESH:D003643), lactose intolerance (MESH:D007787), bronchitis (MESH:D001991), infection (MESH:D007239), gastrointestinal disorders (MESH:D005767), cough (MESH:D003371), joint pain (MESH:D018771), bleeding ulcer (MESH:D014456), bacterial infections (MESH:D001424), allergic reaction (MESH:D004342), gastritis (MESH:D005756), pancreatic and gallbladder disease (MESH:D010182), CAP (MESH:D003147), chronic diseases (MESH:D002908), infectious diseases (MESH:D003141), injury to (MESH:D014947), respiratory infections (MESH:D012141), inflammation (MESH:D007249), gastrointestinal problems (MESH:D012817), respiratory diseases (MESH:D012140), skin conditions (MESH:D012871), renal insufficiency (MESH:D051437), dyspnea (MESH:D004417), IPDV (MESH:D008171), pleural empyema (MESH:D016724), malignancy (MESH:D009369), cow's milk protein allergy (MESH:D016269), abdominal pain (MESH:D015746), liver cirrhosis (MESH:D008103), lung injury (MESH:D055370), nausea (MESH:D009325), alveolar infiltrates (MESH:D017254), chest pain (MESH:D002637), bacterial pneumonia (MESH:D018410), diarrhea (MESH:D003967), Pneumonia (MESH:D011014), fever (MESH:D005334), acute (MESH:D000208), celiac disease (MESH:D002446), vomiting (MESH:D014839), bronchopneumonia (MESH:D001996)
- **Chemicals:** Vitamins C and E (-), cephalosporin (MESH:D002511), ceftriaxone (MESH:D002443), macrolide (MESH:D018942), fluoroquinolone (MESH:D024841), fatty acids (MESH:D005227), magnesium (MESH:D008274), azithromycin (MESH:D017963), Zinc (MESH:D015032), oxygen (MESH:D010100), lactose (MESH:D007785), Free fatty acids (MESH:D005230), iron (MESH:D007501), vitamin A (MESH:D014801), vitamin C (MESH:D001205), methicillin (MESH:D008712)
- **Species:** Staphylococcus aureus (species) [taxon 1280], Homo sapiens (human, species) [taxon 9606], Equus asinus (African ass, species) [taxon 9793], Fungi (kingdom) [taxon 4751]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12937367/full.md

## References

50 references — full list in the complete paper: https://tomesphere.com/paper/PMC12937367/full.md

---
Source: https://tomesphere.com/paper/PMC12937367